Evotec SE has expanded its strategic partnership with Celmatix Inc., a precision health company in the fields of reproductive medicine and fertility leveraging big data and genomics.

Under the terms of the expanded agreement both companies would collaborate to develop preclinical programs for highly prevalent, yet underserved conditions affecting women’s reproductive health including endometriosis, polycystic ovary syndrome (PCOS), and infertility.

Dr. Werner Lanthaler, chief executive officer of Evotec, said, “Over the last 10 years, Celmatix has built the largest, proprietary multi-omics datasets and multidisciplinary expertise in women’s reproductive health. Coupled with our experience developing drugs for hundreds of novel biological targets with top pharmaceutical companies worldwide, we have seen indisputable evidence that data-driven target selection bolsters long-term success for new drug programs. Celmatix is changing the paradigm for women’s health, and we are thrilled to be a part of that remarkable endeavor.”

“Celmatix was founded on the idea that big data and genomics could be harnessed to provide women reproductive health information earlier in life, helping to drive better decision-making,” explained Dr Piraye Yurttas Beim, founder and chief executive officer, Celmatix. “These insights, however, are only as powerful as the number of choices a woman has about what to do next, and so the logical next step for us was to also help expand the toolbox in the hands of physicians to help women achieve better health outcomes, more efficiently. This kind of precision health has been revolutionary for categories like oncology, and we are excited about the impact that our alliance with Evotec will have on the field of women’s reproductive health.”